393 related articles for article (PubMed ID: 30340072)
21. Immune correlates of hepatitis B surface antigen spontaneous seroconversion in hepatitis B e antigen negative chronic hepatitis B patients.
Vyas AK; Sharma BC; Sarin SK; Trehanpati N
Liver Int; 2018 Jan; 38(1):38-49. PubMed ID: 28500636
[TBL] [Abstract][Full Text] [Related]
22. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
[TBL] [Abstract][Full Text] [Related]
23. [Peripheral blood CD4⁺;CXCR5⁺; follicular helper T cells are related to hyperglobulinemia of patients with chronic hepatitis B].
Ma Z; Xie Y; Wang Y; Ma L; He Y; Zhang Y; Lian J; Guo Y; Jia Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 May; 29(5):515-8, 521. PubMed ID: 23643274
[TBL] [Abstract][Full Text] [Related]
24. Screening for serum biomarkers in patients with chronic hepatitis B with hepatitis B surface antigen seroclearance, following pegylated interferon alpha therapy.
Wang Z; Li X; Shi C; Zhang M; Chen R; Wu W; Hou Q; Ke W; Fan T; Wen Z; Hao X; Qu N
Mol Med Rep; 2015 Jan; 11(1):427-33. PubMed ID: 25324041
[TBL] [Abstract][Full Text] [Related]
25. [Alterations of IFN-γ and IL-4 of peripheral blood T cells in patients with chronic HBV infection].
Li M; Sun X; Zhou Z; Zhang X; Jin S; Gao Y; Gao Y
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Feb; 32(2):240-4. PubMed ID: 26927386
[TBL] [Abstract][Full Text] [Related]
26. IL-33 Enhances Humoral Immunity Against Chronic HBV Infection Through Activating CD4(+)CXCR5(+) TFH Cells.
Zhao PW; Shi X; Li C; Ayana DA; Niu JQ; Feng JY; Wang J; Jiang YF
J Interferon Cytokine Res; 2015 Jun; 35(6):454-63. PubMed ID: 25714983
[TBL] [Abstract][Full Text] [Related]
27. Early serum hepatitis B virus large surface protein level: a stronger predictor of virological response to peginterferon alfa-2a than that to entecavir in HBeAg-positive patients with chronic hepatitis B.
Zhu X; Gong Q; Yu D; Zhang D; Gu L; Han Y; Chen J; Zhang Y; Zhang X
J Clin Virol; 2013 Aug; 57(4):318-22. PubMed ID: 23639294
[TBL] [Abstract][Full Text] [Related]
28. Frequency of CD4+CXCR5+ TFH cells in patients with hepatitis b virus-associated membranous nephropathy.
Liu Y; Zhao P; Qu Z; Ayana DA; Jiang Y
Int Immunopharmacol; 2014 Sep; 22(1):98-106. PubMed ID: 24975830
[TBL] [Abstract][Full Text] [Related]
29. Circulating CXCR5
Ekman I; Ihantola EL; Viisanen T; Rao DA; Näntö-Salonen K; Knip M; Veijola R; Toppari J; Ilonen J; Kinnunen T
Diabetologia; 2019 Sep; 62(9):1681-1688. PubMed ID: 31270583
[TBL] [Abstract][Full Text] [Related]
30. Upregulation of NKG2C+ natural killer cells, TLR-2 expression on monocytes and downregulation of regulatory T-cells influence PEG-IFN treatment efficacy in entecavir-suppressed patients with CHB.
Yan W; Wu D; Wang X; Chen T; Lai Q; Zheng Q; Jiang J; Hou J; Han M; Ning Q
Antivir Ther; 2015; 20(6):591-602. PubMed ID: 25814467
[TBL] [Abstract][Full Text] [Related]
31. Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B.
Sonneveld MJ; Rijckborst V; Zeuzem S; Heathcote EJ; Simon K; Senturk H; Pas SD; Hansen BE; Janssen HL
Hepatology; 2012 Jul; 56(1):67-75. PubMed ID: 22307831
[TBL] [Abstract][Full Text] [Related]
32. Use of quantitative serum HBsAg for optimization of therapy in chronic hepatitis B patients treated with pegylated interferon alfa-2a: a Romanian cohort study.
Gheorghiţa VI; Caruntu FA; Curescu M; Olaru I; Radu MN; Colţan G; Streinu-Cercel A
J Gastrointestin Liver Dis; 2013 Mar; 22(1):27-32. PubMed ID: 23539387
[TBL] [Abstract][Full Text] [Related]
33. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.
Rijckborst V; Hansen BE; Cakaloglu Y; Ferenci P; Tabak F; Akdogan M; Simon K; Akarca US; Flisiak R; Verhey E; Van Vuuren AJ; Boucher CA; ter Borg MJ; Janssen HL
Hepatology; 2010 Aug; 52(2):454-61. PubMed ID: 20683945
[TBL] [Abstract][Full Text] [Related]
34. Hepatitis B virus-specific T-cell responses during IFN administration in a small cohort of chronic hepatitis B patients under nucleos(t)ide analogue treatment.
Sprinzl MF; Russo C; Kittner J; Allgayer S; Grambihler A; Bartsch B; Weinmann A; Galle PR; Schuchmann M; Protzer U; Bauer T
J Viral Hepat; 2014; 21(9):633-41. PubMed ID: 24251783
[TBL] [Abstract][Full Text] [Related]
35. CD56
Shi A; Zhang X; Xiao F; Zhu L; Yan W; Han M; Luo X; Chen T; Ning Q
J Viral Hepat; 2018 Nov; 25(11):1352-1362. PubMed ID: 29888839
[TBL] [Abstract][Full Text] [Related]
36. Clinical characteristics of chronic hepatitis B cured by peginterferon in combination with nucleotide analogs.
Bao X; Guo J; Xiong F; Qu Y; Gao Y; Gu N; Lu J
Int J Infect Dis; 2020 Jul; 96():562-566. PubMed ID: 32474201
[TBL] [Abstract][Full Text] [Related]
37. Study on the distribution of CD8+ memory T cell subsets and IFN-γ level during the spontaneous clearance of hepatitis B virus in patients with chronic hepatitis B virus infection.
Ma XJ; Chen XF; Chen WL; Chen R; Huang J; Luo XD; Liao JY; Chen XP
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(20):4675-4679. PubMed ID: 29131246
[TBL] [Abstract][Full Text] [Related]
38. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.
Brunetto MR; Moriconi F; Bonino F; Lau GK; Farci P; Yurdaydin C; Piratvisuth T; Luo K; Wang Y; Hadziyannis S; Wolf E; McCloud P; Batrla R; Marcellin P
Hepatology; 2009 Apr; 49(4):1141-50. PubMed ID: 19338056
[TBL] [Abstract][Full Text] [Related]
39. Quantification of HBsAg and HBV-DNA during therapy with peginterferon alpha-2b plus lamivudine and peginterferon alpha-2b alone in a German chronic hepatitis B cohort.
Wiegand J; Brosteanu O; Kullig U; Wiese M; Berr F; Maier M; Tillmann HL; Schiefke I
Z Gastroenterol; 2011 Nov; 49(11):1463-9. PubMed ID: 22069045
[TBL] [Abstract][Full Text] [Related]
40. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
